CancerDrs

Breast Cancer clinical trials in Illinois

41 actively recruiting breast cancer trials at 70 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • OSF Saint Joseph Medical Center — Bloomington, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Illinois:
  • Centralia Oncology Clinic — Centralia, Illinois
  • Northwestern University — Chicago, Illinois
  • Rush MD Anderson Cancer Center — Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
  • Carle at The Riverfront — Danville, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Illinois:
  • Northwestern Medicine — Chicago, Illinois
  • Rush University Medical Center — Chicago, Illinois
  • University of Illinois — Chicago, Illinois
  • University of Chicago Medical Center — Chicago, Illinois
  • NorthShore University Healthsystem — Evanston, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Illinois:
  • Research Site — Chicago, Illinois
  • Research Site — Elmhurst, Illinois
  • Research Site — Naperville, Illinois
  • Research Site — Park Ridge, Illinois
  • Research Site — Plainfield, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…

Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Illinois:
  • City of Hope, Chicago — Chicago, Illinois
  • Northwestern Memorial Hospital — Chicago, Illinois
  • University of Illinois at Chicago — Chicago, Illinois
  • Accellacare of Duly — Lisle, Illinois
  • Simmons Cancer Institute at SIU — Springfield, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Illinois:
  • Memorial Hospital. — Shiloh, Illinois
  • Orchard Healthcare Research Inc. — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Illinois:
  • Affiliated Oncologists IL — Chicago, Illinois
  • Hope And Healing Care — Hinsdale, Illinois
  • Midwestern Reg MC COH Chicago — Zion, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in Illinois:
  • Clinical Trial Site — Chicago, Illinois
  • Clinical Trial Site — Chicago, Illinois
  • Clinical Trial Site — Urbana, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Illinois:
  • Northwestern University - Northwestern Memorial Hospital — Chicago, Illinois
  • City of Hope - Cancer Center Chicago — Zion, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…

Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Illinois:
  • Research Site — Chicago, Illinois
  • Research Site — Chicago Ridge, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Illinois:
  • Clinical Trial Site — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…

Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in Illinois:
  • Cancer Care Specialists — Decatur, Illinois
  • Cancer Care Specialists of Illinois — O'Fallon, Illinois
  • Carle Foundation Hospital d/b/a Carle Cancer Center — Urbana, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Illinois:
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • SIH Cancer Institute — Carterville, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in Illinois:
  • Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Illinois:
  • University of Illinois Cancer Center — Chicago, Illinois
  • The University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…

Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Illinois:
  • City of Hope Chicago — Zion, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Illinois:
  • Local Institution - 0125 — Maywood, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast cancer previous…

Sponsor: Northwestern University
NCT ID: NCT03213041
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 41 trials with sites in Illinois. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25